Relative to other highly prevalent diseases such as cancers or cardiovascular disease, companies seeking therapies for neurodegeneration have struggled with drug delivery and biomarker validation inside the brain.  Recent approvals of anti-amyloid therapies show one area of progress, with multiple other therapeutic approaches in clinical development. This session will feature companies describing new modalities and techniques for reaching diseased brain cells and measuring results to improve cognitive health for patients.